SBIR TOPIC 255, PHASE I: DEVELOPMENT OF ANTICANCER VATPASE INHIBITORS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO110085
Agency Tracking Number: N43CO110085
Amount: $199,931.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: NCI
Solicitation Number: N/A
Small Business Information
OMM SCIENTIFIC INC
2600 N STEMMONS FWY STE 129, DALLAS, TX, 75207-2119
DUNS: 610369535
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DONALD STEWART
 (214) 350-9156
 DSTEWART@OMMSCIENTIFIC.COM
Business Contact
 DONALD STEWART
Phone: (214) 350-9156
Email: DSTEWART@OMMSCIENTIFIC.COM
Research Institution
 Stub
Abstract
Invasive, metastatic, and/or drug resistant cancers are responsible for most cancer deaths. Development of a drug that blocks these phenotypes to improve outcomes is the ultimate objective. The specific means is by inhibiting the acidification of extra-cellular and extra-tumoral environments that otherwise facilitates invasion, metastasis, and drug resistance. The lead, RD203, potently inhibits the V-ATPase pump largely responsible for acidification and shows compelling anticancer activities. However, it requires continuous infusion for in vivo efficacy, an impediment to further development. Synthesis and testing of prod rugs of RD203 that mimic the exposure and compelling in vivo efficacy of continuous infusion is the challenging innovation and overall objective of this proposal. RD203 will be synthesized and used to prepare several types of each of three classes of prod rugs designed to release free RD203 slowly and/or target release at the tumor site. The modifications were selected for safety, develop-ability, and precedence in previous clinical development. The prodrugs will be screened and winnowed down by testing for useful: (a) chemical stability, (b) MTD, (c) desired pharmacokinetic profile, and (d) in vivo efficacy with daily doses. Fromthis process one or two RD203 prodrugs will be selected for further development. Provide

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government